Alector, Inc. (ALEC), a clinical-stage biotechnology company based in South San Francisco, develops therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's using its proprietary Alector Brain Carrier (ABC) blood-brain-barrier delivery platform. After a volatile stretch driven by pipeline setbacks and a major licensing deal, investors are asking whether the shares can climb to an average analyst price target of $3.90.
Five current, attributable analyst targets were reviewed. The most bullish is H.C. Wainwright's $8.00 target (Buy, raised from $5.00 in mid-October 2026), which describes Alector as a platform company rather than a single-asset story. BTIG maintains a Buy with a $6.00 target. At the cautious end, Bank of America Securities holds a Sell rating with a $1.00 target, while Morgan Stanley carries an Underweight rating with a $3.00 target, and Mizuho Securities maintains a Hold with a $1.50 target. The low-to-high range is therefore $1.00 to $8.00, with a calculated mean of $3.90.
This wide spread reflects genuine disagreement about how to value the pipeline. Bullish firms emphasize external validation of the ABC platform and future partnering potential, while cautious firms argue the company's cash runway and early-stage programs do not yet justify a higher valuation. Notably, the $3.90 mean aligns with an independently reported average from S&P Global data, which also shows a consensus "Hold" rating across seven analysts, several of whom do not publish numeric targets.
Alector shares have traded in a wide 52-week range of roughly $1.09 to $2.76. Following the early-October 2026 announcement of the Genentech licensing agreement, the stock re-rated sharply before settling back, and it recently traded near $2.07. Reaching $3.90 would require an increase of about 88%, a very large move. That would take the shares well above their 52-week high of $2.76 and into territory not seen since before the company's 2024–2025 pipeline disappointments.
The clearest positive catalyst is the global license deal with Genentech, a unit of Roche, for AL050, a brain-penetrant GCase enzyme replacement therapy for Parkinson's disease. The agreement includes a $100 million upfront payment, up to $1.17 billion in development, regulatory, and commercial milestones, and tiered royalties. Management said the deal extends the company's cash runway into 2029, reducing near-term dilution risk while funding its wholly owned programs. Additional support could come from advancing AL137, its anti-amyloid-beta antibody for Alzheimer's, toward clinical data, and from further validation of the ABC platform across antibody, enzyme, and siRNA (small interfering RNA) applications.
The principal obstacle is execution risk. Alector has already suffered the failure of its latozinemab (AL001) program in a Phase 3 trial for frontotemporal dementia, a Phase 2 miss for AL002 in Alzheimer's disease, and a setback for AL101, which contributed to a workforce reduction of about 49%. The remaining pipeline is largely early-stage, with limited near-term data catalysts, and the company continues to consume cash even after the Genentech deal. Cautious analysts explicitly frame the deal as a way to extend cash runway rather than as proof of long-term equity upside, and any clinical setback could compress the multiple sharply.
The 52-week high near $2.76 stands as the most relevant near-term resistance; a sustained move above it would be required before the $3.90 target becomes approachable. The psychological $3.00 level also marks a meaningful zone given Morgan Stanley's $3.00 target. On the downside, the $1.50 to $1.83 area has acted as support during recent pullbacks, with the 52-week low near $1.09 representing the deeper downside reference point.
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms vary and no firm timetable is guaranteed. Investors should monitor upcoming earnings and guidance, any analyst revisions following new data, clinical progress on AL137 and the broader ABC platform, and whether additional milestone payments from the Genentech collaboration materialize. Regulatory updates and broader biotech-sector risk appetite are also relevant, given the stock's sensitivity to financing conditions and binary clinical outcomes.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use the tool to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. For investors tracking a volatile name like Alector, automated signal monitoring can help surface changes in trend and momentum alongside the fundamental picture.
The $3.90 target is the arithmetic mean of five widely divergent analyst targets spanning $1.00 to $8.00, and it sits about 88% above the recent share price near $2.07. The bull case rests on the Genentech deal, an extended cash runway, and the optionality of the ABC platform, while the bear case emphasizes past clinical failures, heavy cash consumption, and a sparse near-term catalyst calendar. With such a wide target range, the average figure is best understood as a midpoint of genuinely conflicting views rather than a forecast. Whether the shares approach $3.90 will likely hinge on clinical data delivery, additional partnership validation, and the company's ability to preserve capital while advancing its pipeline.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ALEC has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALEC jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To ALEC | 1D Price Change % | ||
|---|---|---|---|---|
| ALEC | 100% | +3.67% | ||
| EDIT - ALEC | 49% Loosely correlated | +1.40% | ||
| BCYC - ALEC | 47% Loosely correlated | -2.32% | ||
| VYGR - ALEC | 43% Loosely correlated | +1.76% | ||
| ARVN - ALEC | 43% Loosely correlated | -0.73% | ||
| PRTA - ALEC | 42% Loosely correlated | -0.85% | ||
More | ||||